Back to results
US 2026/0259209 A1Published application
Targeting aberrant o-glycans of iga1 to develop a urinary diagnostic method for iga nephropathy
AssigneeBuddhist Tzu Chi Medical Foundation
InventorsAnn CHEN, Shuk-Man Ka
Life of this patent
Estimating the term…
Abstract
The current invention provides high specificity monoclonal antibodies or lectins as probes, which can specifically bind to Gd-IgA as a novel non-invasive method for rapid detecting of urinary samples from IgAN subjects, which can elevate effectively to diagnosing IgA nephropathy.
Claims12
A method for detecting galactose-deficient O-glycosyl IgA1, comprising:
- (a) obtaining a urinary sample from a subject;
- and
- (b) using a first probe in a first immunoassay to detect galactose deficient O-glycosyl IgAQ1 in the subject;
- wherein the probe is a CGL,
- wherein the CGL set forth in SEQ ID NO:1;
- (c) using a second probe in a second immunoassay to detect galactose deficient O-glycosyl IgAQ1 in the subject;
- wherein the second probe is an IgG monoclonal antibody,
- wherein the IgG monoclonal antibody is selected from SEQ ID NO:
- 2, and SEQ ID NO:
- 3.
7 more elements
A method for diagnosing a urinary sample from a subject with galactose-deficient O-glycosyl IgA1, comprising:
- (a) using a first probe in a first immunoassay;
- and
- (b) determining whether the first probe binds to galactose-deficient O-glycosyl of IgA1, the binding of the first probe to galactose-deficient O-glycosyl of IgAQ1 indicating that the subject has or is at risk of developing galactose-deficient O-glycosyl of IgA1;
- wherein the first probe is a CGL,
- wherein the CGL set forth in SEQ ID NO:
- 1
- (c) using a second probe in a second immunoassay;
- and
- (d) determining whether the second probe binds to galactose-deficient O-glycosyl of IgA1, the binding of the second probe to galactose-deficient O-glycosyl of IgAQ1 indicating that the subject has or is at risk of developing galactose-deficient O-glycosyl of IgA1;
- wherein the second probe is an IgG monoclonal antibody,
- wherein the IgG monoclonal antibody is selected from SEQ ID NO:
- 2, and SEQ ID NO:
- 3.
10 more elements
A method for detecting or diagnosing galactose-deficient O-glycosyl IgA1, comprising:
- (a) obtaining a urinary sample from a subject;
- and
- (b) using a probe in an immunoassay for determining whether the probe binds to galactose-deficient O-glycosyl of IgA1, the binding of the probe to galactose-deficient O-glycosyl of IgAQ1 indicating that the subject has or is at risk of developing galactose-deficient O-glycosyl of IgA1;
- wherein the probe is a CGL or an IgG monoclonal antibody,
- wherein the CGL set forth in SEQ ID NO:1,
- wherein the IgG monoclonal antibody is selected from SEQ ID NO:
- 2, and SEQ ID NO:
- 3.
5 more elements
Dependencies are inferred from the claim text.